The Filing Desk

Definitive Healthcare

DH · Nasdaq · Information Technology · Financials, fiscal 2020 to 2025

DH · Last close · November 19, 2026
$1.21
Value Definitive Healthcare yourself

Definitive Healthcare's revenue fell 4.2% to $242 million in fiscal 2025. Its operating margin was −92.9%, up from −281.9% a year earlier. Free cash flow was $37 million, down 19.2%. It paid out $49 million in dividends and buybacks, 133% of free cash flow. The diluted share count fell 8.6%.

Definitive Healthcare Corp. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076782 Updated
Revenue
$242M
4.2%
Operating margin
−92.9%
189.0 pts
Net income
−$139M
 
Free cash flow
$37M
19.2%
Return on capital
−38.3%
27.4 pts
Market cap
$129M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Definitive Healthcare does

Definitive Healthcare sells data about the US health care system. Its online products describe hospitals, health systems, doctors and other care providers and what they do, drawing on thousands of data sources, including insurance claims. Companies that sell to health care organizations use it to find new markets, plan sales and reach the right decision makers.

It serves three main kinds of customers: life sciences companies that make drugs and medical devices; providers such as hospitals and health systems; and a mixed group that includes health care technology firms, staffing firms, real estate firms, banks and ad agencies. Customers pay for subscriptions, which bring in almost all of its revenue. It had about 2,330 customers at the end of 2025. It names competitors including IQVIA, Clarivate, Komodo Health, Veeva and ZoomInfo.

Founded in 2011 and based in Framingham, Massachusetts, the company had 686 employees at the end of 2025, most of them in the United States and the rest in Europe and India. The listed company is a holding company that owns about 73.1% of the business it runs.

Its biggest risks, as it describes them

  • Almost all its revenue comes from subscriptions, so falling demand for its data would hurt it badly.
  • Losing access to the outside providers whose data it relies on.
  • Strong competition, and rivals whose data could become deeper or more accurate than its own.
  • Failing to win new customers or get current ones to subscribe to more.
  • It may not reach or keep a profit as it invests in the business.
From Definitive Healthcare's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Definitive Healthcare lost money in fiscal 2025: a net loss of $139 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments388332308290181
Debt incl. finance leases273266258244166
Net debt (negative means net cash)−114−66−50−46−15
Net debt to EBITDA—————
Debt to equity0.2x0.2x0.2x0.4x0.4x
Interest coverage−1.1x−3.9x−21.7x−47.9x−19.9x
Current ratio3.6x2.9x2.3x2.3x1.6x
Quick ratio3.6x2.9x2.3x2.3x1.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Definitive Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Definitive Healthcare reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 93 of 95 of 9
Rule of 4028.1%18.5%11.1%
Altman Z''1.19−3.72−3.49
Accruals ratio−12.3%−32.3%−21.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailPass
Gross margin rosePassFailFail
Revenue rose relative to assetsPassPassPass
F-score4 of 93 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Definitive Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Definitive HealthcareFY25−4.2%−92.9%15.3%−38.3%—5
VTEXFY256.1%7.5%13.4%39.9%−9.0x6Compare
DoceboFY2511.9%9.6%11.2%—−2.8x5Compare
OneSpanFY250.0%19.9%20.8%———Compare
C3.aiFY26−35.7%−199.2%−76.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue118166223251252242
Revenue growth—40.4%34.0%12.9%0.3%−4.2%
Gross profit88126180204198183
Research and development111935423635
Operating income−16−27−44−330−711−224
Net income0−18−7−202−413−139
Diluted EPS (US$)—−0.19−0.07−1.79−3.54−1.30
Diluted shares (millions)—92101113117107
Cash flow
Cash from operations232536415854
Capital expenditure17831217
Free cash flow221827384637
Dividends paid000000
Share buybacks0232002250
Acquisitions22405645140
Stock-based compensation21036493829
Balance sheet at fiscal year end
Cash and short-term investments25388332308290181
Debt incl. finance leases462273266258244166
Total assets1,7472,1182,1231,8261,089736
Total liabilities554618641627482356
Shareholders' equity1,1931,5001,4821,199607379
Margins and ratios
Gross margin74.2%75.5%80.9%81.1%78.3%75.9%
Operating margin−13.4%−16.4%−19.8%−131.2%−281.9%−92.9%
Net margin0.0%−10.7%−3.2%−80.5%−163.8%−57.5%
Free cash flow margin18.4%11.1%12.2%15.2%18.2%15.3%
Rule of 40 (growth + FCF margin)—51.5%46.2%28.1%18.5%11.1%
Return on capital—−1.4%−2.5%−20.3%−65.7%−38.3%
Return on equity—−1.3%−0.5%−15.1%−45.7%−28.2%
Return on assets—−0.9%−0.3%−10.2%−28.3%−15.2%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Definitive Healthcare's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Definitive Healthcare.